Total recall

Carmichael, Helen; Odriscoll, Cath
December 2004
European Chemical News;12/6/2004, Vol. 81 Issue 2127, p20
Trade Publication
Discusses issues behind the withdrawal of Vioxx, a Cox-2 inhibitor arthritis drug, by Merck from the market on September 30, 2004 due to evidence that it increased the risk of heart attacks and strokes. Estimated sales of Vioxx in 2004 according to Marc Hennebert, a partner at Strategic Decisions Group; Impact of Vioxx withdrawal on Arcoxia NDA drug; Value of legal costs faced by the company according to Richard Evans, analyst from Stanford C Bernstein Research; Difficulty to prove personal injury claims against the drug. INSET: Off the shelves and into court.


Related Articles

  • The Raging COX-2 CONTROVERSY.  // Total Health;Sep2006, Vol. 28 Issue 3, p37 

    The article focuses on the controversy over the side-effects of painkillers known as type 2 cyclooxygenase (COX-2) inhibitors. Soon after Merck's Vioxx was taken off the market, the U.S. Food and Drug Administration (FDA) asked Pfizer to recall Bextra, one of its COX-2 inhibitors, because of the...

  • ARTHRITIS after Vioxx. Huemer, Richard P. // Life Extension;Feb2005, Vol. 11 Issue 2, p34 

    Focuses on Merck's voluntary worldwide withdrawal of its arthritis drug Vioxx from the market. Promotion of Vioxx and other cyclooxygenase-2 inhibitors as wonder drugs because of their ability to relieve arthritis pain without causing stomach problems; Decision of Merck in relation to reports of...

  • The Impact of Vioxx on US drug regulation.  // Reactions Weekly;12/3/2005, Issue 1080, p2 

    The article discusses research being done on the impact Merck & Co's Vioxx on U.S. drug regulations. It references a study by T. Zwillich published in the November 19, 2005 issue of "Lancet." Merck & Co.'s COX-2 inhibitor Vioxx has been accused of resulting to a myocardial infarction or...

  • Arthritis sufferers still suffering. Johnsen, Michael // Drug Store News;4/11/2005, Vol. 27 Issue 5, p31 

    Reports that arthritis sufferers in the United States are still in search for pain relief months after Merck's recall of the Vioxx cox-2 inhibitor in September 204. Linkage of Vioxx as well as Celebrex and Bextra to heart disease; Failure of the Food a and Drug Administration to issue any...

  • TRYING TO LOOK PATS VIOXX.  // njbiz;10/25/2004, Vol. 17 Issue 42, p2 

    Reports on the impact of the recall of the painkiller Vioxx by Whitehouse, New Jersey-based Merck on other Cox-2 inhibitors. Reason for recalling the drug; Results of a study conducted by Pfizer on whether its Cox-2 product could help prevent further cardiac problems in patients with a history...

  • First Vioxx, Then Bextra, Now Celebrex? Siegfried, Donna Rae // Arthritis Today;Mar/Apr2005, Vol. 19 Issue 2, p52 

    Deals with the withdrawal of the celocoxib drug, Celebrex from the market. Link of Celebrex with the risk of heart attack; Incidence of heart attack among people with colon polyps who take Celebrex; Other top-selling cyclooxygenase-2 inhibitors that have been recalled.

  • A Painful Mistake. Gorman, Christine; Kher, Unmesh // Time;10/11/2004, Vol. 164 Issue 15, p48 

    This article discusses the impact of pharmaceutical giant, Merck, pulling its arthritis drug, Vioxx, off the market because of its health risks. A pharmaceutical company can rise and fall on the strength of a handful of blockbuster drugs, Vioxx was a giant. Unveiled with great fanfare by Merck...

  • COX 2 inhibitors may increase risk of heart attack. Gottlieb, Scott // BMJ: British Medical Journal (International Edition);9/1/2001, Vol. 323 Issue 7311, p471 

    Reports that certain cyclooxygenase (COX) 2 inhibitors, non-steroidal anti-inflammatory drugs that relieve the pain associated with arthritis, may increase the risk of heart attack. Research at the Cleveland Clinic Foundation in Ohio which compared cardiovascular events among patients taking...

  • Rofecoxib withdrawal sparks immediate switch to alternatives.  // PharmacoEconomics & Outcomes News;10/23/2004, Issue 464, p11 

    Presents the results of a study on the role of withdrawal by Merck & Co. of rofecoxib in promoting patient switch to alternative therapies in the U.S., as of September 2004. Number of recipients of rofecoxib prescriptions who received prescriptions for alternative therapies; Percentage of an...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics